Publications
2024
Dynamic changes in tumor profiling reveal intra- and intertumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient
2024
Liquid Biopsy for Detection of Pancreaticobiliary Cancers by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and Their Clusters
2023
Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies
2022
Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells
2022
Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types
2021
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report
2021
Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors
2021
Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers
2021
Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers
2020
Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk
2020
Evaluation of Circulating Tumor Cell Clusters for Pan-Cancer Noninvasive Diagnostic Triaging
2020
A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer
2020
Clinical utility of circulating tumor‑associated cells to predict and monitor chemo‑response in solid tumors
2020
Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen
2019
Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer
2019
Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial
2019
Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC